Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2017-07-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.1706055114PMID 28739923PMCID PMC5559039
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glypican-1 in exosomes as biomarker for early detection of pancreatic cancer.

  2016cited by this paper
• Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma

  2016cited by this paper
• Immunogenicity of therapeutic recombinant immunotoxins

  2016cited by this paper
• Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy

  2016cited by this paper
• Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

  2016influential reference
• Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signaling and protein synthesis

  2015cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cited by this paper
• Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells

  2014cited by this paper
• Improved vectors and genome-wide libraries for CRISPR screening

  2014cited by this paper
• Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma

  2014cited by this paper
• Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican‐3 for liver cancer therapy

  2014cited by this paper
• Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis

  2014cited by this paper
• Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression

  2013cited by this paper
• Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma

  2013cited by this paper
• Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors

  2013cited by this paper
• Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

  2013cited by this paper
• Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission.

  2012cited by this paper
• B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

  2012cited by this paper
• Identification of Cell Surface Proteins as Potential Immunotherapy Targets in 12 Pediatric Cancers

  2012cited by this paper
• Wnt/β-catenin signaling and disease.

  2012cited by this paper
• Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

  2011cited by this paper
• Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

  2011cited by this paper
• In Vivo Imaging of Human Malignant Mesothelioma Grown Orthotopically in the Peritoneal Cavity of Nude Mice

  2011influential reference
• Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

  2010cited by this paper
• Glypican‐3 expression is correlated with poor prognosis in hepatocellular carcinoma

  2009cited by this paper
• Lentivirus‐mediated bifunctional cell labeling for in vivo melanoma study

  2009cited by this paper
• In vitro antibody affinity maturation targeting germline hotspots.

  2009cited by this paper
• Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.

  2009cited by this paper
• Wnt and FGF signals interact to coordinate growth with cell fate specification during limb development

  2008cited by this paper
• Deregulated Wnt/β-catenin program in high-risk neuroblastomas without MYCN amplification

  2008cited by this paper
• Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain.

  2008cited by this paper
• Heparin activates Wnt signaling for neuronal morphogenesis

  2008cited by this paper
• Glypicans

  2008cited by this paper
• A Phase I Clinical Trial of Single-Dose Intrapleural IFN-β Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses

  2007cited by this paper
• Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies.

  2006cited by this paper
• Wnt/beta-catenin signaling acts upstream of N-myc, BMP4, and FGF signaling to regulate proximal-distal patterning in the lung.

  2005cited by this paper
• Essential role of non-canonical Wnt signalling in neural crest migration

  2005cited by this paper
• Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.

  2005cited by this paper
• In Vitro Antibody Evolution Targeting Germline Hot Spots to Increase Activity of an Anti-CD22 Immunotoxin*

  2005cited by this paper
• Instructive Role of Wnt/ß-Catenin in Sensory Fate Specification in Neural Crest Stem Cells

  2004cited by this paper
• Crystal Structure of a Shark Single-Domain Antibody V Region in Complex with Lysozyme

  2004cited by this paper
• Faculty Opinions recommendation of Instructive role of Wnt/beta-catenin in sensory fate specification in neural crest stem cells.

  2004cited by this paper
• Neuroblastoma: biological insights into a clinical enigma

  2003cited by this paper
• beta-Catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system.

  2003cited by this paper
• Regulation of Cerebral Cortical Size by Control of Cell Cycle Exit in Neural Precursors

  2002cited by this paper
• Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays.

  2002cited by this paper
• The Hedgehog and Wnt signalling pathways in cancer

  2001cited by this paper
• Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

  1999cited by this paper
• Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid

  1999cited by this paper
• Expression of the heparan sulfate proteoglycan glypican‐1 in the developing rodent

  1998cited by this paper
• Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

  1998cited by this paper
• Expression of OCI-5/glypican 3 during intestinal morphogenesis: regulation by cell shape in intestinal epithelial cells.

  1997cited by this paper
• Expression of the cell surface proteoglycan glypican-5 is developmentally regulated in kidney, limb, and brain.

  1997cited by this paper
• Cerebroglycan, a developmentally regulated cell-surface heparan sulfate proteoglycan, is expressed on developing axons and growth cones.

  1997cited by this paper
• A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma.

  1995cited by this paper
• Cerebroglycan: an integral membrane heparan sulfate proteoglycan that is unique to the developing nervous system and expressed specifically during neuronal differentiation

  1994cited by this paper
• Neuronal expression of glypican, a cell-surface glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan, in the adult rat nervous system

  1994cited by this paper
• Immunotoxin therapy of cancer.

  1993cited by this paper
• Immunotoxin therapy of cancer.

  1993cited by this paper
• Gene amplification in human neuroblastomas: basic mechanisms and clinical implications.

  1986cited by this paper
• Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.

  1985cited by this paper
• Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

  1984cited by this paper

• A polysaccharide from Arthrospira platensis alleviates pancreatic cancerassociated with negatively regulating galectin-3 and glypican-6 expression.

  2026cites this paper
• Human VH-antibody-based CAR T cells targeting folate receptor-alpha show enhanced persistence and reduced T-cell exhaustion against ovarian cancer.

  2026cites this paper
• Structural Features of Glypicans and Their Impact on Wnt Signaling in Cancer

  2025cites this paper
• A new treatment for canine B-cell lymphoma based on a recombinant single-domain antibody immunotoxin derived from Pseudomonas aeruginosa exotoxin A

  2025cites this paper
• GRP78 Nanobody‐Directed Immunotoxin Activates Innate Immunity Through STING Pathway to Synergize Tumor Immunotherapy

  2025cites this paper
• Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs

  2025cites this paper
• Antibody conjugates in neuroblastoma: a step forward in precision medicine

  2025influential citation
• Defining the extracellular matrix for targeted immunotherapy in adult and pediatric brain cancer

  2025cites this paper
• Reprogramming the neuroblastoma tumor immune microenvironment to enhance GPC2 CAR T cells.

  2025cites this paper
• Functional targeting of Glypican-4 by a conformation-specific single-domain antibody.

  2025cites this paper
• Fine tuning towards the next generation of engineered T cells

  2025cites this paper
• GPC2-CAR T cells have potent preclinical activity against orthotopic medulloblastoma xenografts

  2025cites this paper
• D3-GPC2-directed CAR T cells are safe and efficacious in preclinical models of neuroblastoma and small cell lung cancer.

  2025cites this paper
• Antibody-gamma/delta T cell receptors targeting GPC2 regress neuroblastoma with low antigen density

  2025cites this paper
• Application of nanobody-based CAR-T in tumor immunotherapy (Review)

  2025cites this paper
• Cancer therapy with antibodies

  2024cites this paper
• GPC2 as a diagnostic and prognostic marker regulated progression of colorectal cancer.

  2024cites this paper
• State of the art and perspectives of chimeric antigen receptor T cells cell therapy for neuroblastoma.

  2024cites this paper
• The peptide-based bispecific CAR T cells target EGFR and tumor stroma for effective cancer therapy.

  2024cites this paper
• CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma

  2024cites this paper
• CAR T-cells for pediatric solid tumors: where to go from here?

  2024cites this paper
• Deciphering the endogenous SUMO-1 landscape: a novel combinatorial peptide enrichment strategy for global profiling and disease association

  2024cites this paper
• State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future?

  2024cites this paper
• Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions

  2024cites this paper
• Design principles for engineering light-controlled antibodies.

  2023cites this paper
• CAR-T Therapy in Treating Solid Tumor: Application and Limitations

  2023cites this paper
• Expression Pattern of Tumor-associated Antigens in Neuroblastoma: Association With Cytogenetic Features and Survival.

  2023cites this paper
• Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma

  2023cites this paper
• The Glycosaminoglycan Side Chains and Modular Core Proteins of Heparan Sulphate Proteoglycans and the Varied Ways They Provide Tissue Protection by Regulating Physiological Processes and Cellular Behaviour

  2023cites this paper
• Glypican1: a potential cancer biomarker for nanotargeted therapy.

  2023cites this paper
• Glypicans, 35 years later

  2023cites this paper
• Association between GPC2 polymorphisms and neuroblastoma risk in Chinese children

  2023cites this paper
• Monocyte and Macrophage in Neuroblastoma: Blocking Their Pro-Tumoral Functions and Strengthening Their Crosstalk with Natural Killer Cells

  2023cites this paper
• CAR-T Therapies in Solid Tumors: Opportunities and Challenges

  2023cites this paper
• Heparan sulfate proteoglycans in cancer: Pathogenesis and therapeutic potential.

  2023cites this paper
• Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC

  2023cites this paper
• Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma

  2023cites this paper
• Humanization of the Shark VNAR Single Domain Antibody Using CDR Grafting

  2023cites this paper
• Chemistry and Function of Glycosaminoglycans in the Nervous System.

  2023cites this paper
• A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer

  2022cites this paper
• Neural crest cells development and neuroblastoma progression: Role of Wnt signaling

  2022cites this paper
• CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin

  2022cites this paper
• Development of Glypican-2 Targeting Single-Domain Antibody CAR T Cells for Neuroblastoma.

  2022cites this paper
• The Extracellular Matrix and Neuroblastoma Cell Communication—A Complex Interplay and Its Therapeutic Implications

  2022cites this paper
• The emergence of AntibodyPlus: the future trend of antibody-based therapeutics

  2022cites this paper
• An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma

  2022influential citation
• The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma

  2022cites this paper
• GPC2 deficiency inhibits cell growth and metastasis in colon adenocarcinoma

  2022cites this paper
• 人源化CD19 CAR-T细胞治疗儿童及青少年复发难治急性淋巴细胞白血病患者的疗效及安全性

  2022cites this paper
• Harnessing Human Papillomavirus’ Natural Tropism to Target Tumors

  2022cites this paper
• Reforming the Chimeric Antigen Receptor by Peptide Towards Optimized CAR T Cells With Enhanced Anti-Cancer Potency and Safety

  2022cites this paper
• Emerging applications of nanobodies in cancer therapy.

  2022cites this paper
• Nanobody-based CAR-T cells for cancer immunotherapy

  2022cites this paper
• GPC1-targeted immunotoxins inhibit pancreatic tumor growth in mice via depletion of short-lived GPC1 and downregulation of Wnt signaling.

  2022cites this paper
• Finding New Ways How to Control BACE1

  2022cites this paper
• Integrated Analysis of Energy Metabolism Signature-Identified Distinct Subtypes of Bladder Urothelial Carcinoma

  2022cites this paper
• A novel PD-L1-targeted shark VNAR single domain-based CAR-T strategy for treating breast cancer and liver cancer

  2021cites this paper
• Heparanome-Mediated Rescue of Oligodendrocyte Progenitor Quiescence following Inflammatory Demyelination

  2021cites this paper
• The Application of Nanobody in CAR-T Therapy

  2021cites this paper
• A guide to the composition and functions of the extracellular matrix

  2021cites this paper
• Immunogenicity of CAR T cells in cancer therapy

  2021cites this paper
• Development of Molecules Antagonizing Heparan Sulfate Proteoglycans

  2021cites this paper
• Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma

  2021cites this paper
• Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma

  2021cites this paper
• Selection of human single domain antibodies (sdAb) against thymidine kinase 1 and their incorporation into sdAb-Fc antibody constructs for potential use in cancer therapy

  2021cites this paper
• Biology of Proteoglycans and Associated Glycosaminoglycans

  2021cites this paper
• Advances in immunotherapeutic targets for childhood cancers: a focus on glypican-2 and B7-H3.

  2021cites this paper
• The antigen‐binding moiety in the driver's seat of CARs

  2021cites this paper
• Data-driven approaches to advance research and clinical care for pediatric cancer.

  2021cites this paper
• T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy

  2021cites this paper
• CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice

  2021influential citation
• Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors

  2021cites this paper
• A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope

  2021cites this paper
• The Role of Glypican-1 in Regulating Multiple Cellular Signaling Pathways.

  2021cites this paper
• CAR T cell therapy in solid tumors; with an extensive focus on obstacles and strategies to overcome the challenges.

  2021cites this paper
• Preclinical testing of chimeric antigen receptor T cells in neuroblastoma mouse models

  2021cites this paper
• Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

  2021cites this paper
• GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.

  2021cites this paper
• Selection of Human Single Domain Antibodies (sdAb) Against Thymidine Kinase

  2021cites this paper
• Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains

  2020cites this paper
• Heparan Sulfate Proteoglycan Signaling in Tumor Microenvironment

  2020cites this paper
• Prognostic value of Glypican family genes in early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy and possible mechanisms

  2020cites this paper
• Identification and Validation of an Energy Metabolism-Related lncRNA-mRNA Signature for Lower-Grade Glioma

  2020cites this paper
• Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics

  2020cites this paper
• Role of cell surface proteoglycans in cancer immunotherapy.

  2020cites this paper
• The Role of Glypicans in Cancer Progression and Therapy

  2020cites this paper
• Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update

  2020cites this paper
• A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma

  2020cites this paper
• GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab

  2020influential citation
• Strategies to Improve Chimeric Antigen Receptors Therapies for Neuroblastoma

  2020cites this paper
• Promising Chimeric Antigen Receptors for Non-B-Cell Hematological Malignancies, Pediatric Solid Tumors, and Carcinomas

  2020cites this paper
• Nanobodies in cancer.

  2020cites this paper
• The Use of Quantitative Digital Pathology to Measure Proteoglycan and Glycosaminoglycan Expression and Accumulation in Healthy and Diseased Tissues

  2020cites this paper
• Targets and Antibody Formats for Immunotherapy of Neuroblastoma

  2020cites this paper
• Isolation of rabbit single domain antibodies to B7-H3 via protein immunization and phage display.

  2020cites this paper
• SDAE-GAN: Enable high-dimensional pathological images in liver cancer survival prediction with a policy gradient based data augmentation method

  2020cites this paper
• Ancient species offers contemporary therapeutics: an update on shark VNAR single domain antibody sequences, phage libraries and potential clinical applications.

  2020cites this paper
• Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma

  2020cites this paper
• Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma

  2020cites this paper
• Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.

  2020cites this paper